Indian Generics Press For Compulsory Licenses Concerns Brand Makers
This article was originally published in PharmAsia News
Multinational drug makers are voicing concerns about moves in India to impose compulsory licenses that would free others, mainly Indian manufacturers, to make generic copies of their drugs. Indian generics makers are looking into the possibility of using World Trade Organization provisions that allow patents to be overridden during medical emergencies or when cheaper drugs can be exported to least-developed nations. The Trade-Related Aspects of Intellectual Property Rights provision allows patent holders to receive "adequate remuneration." Natco Pharma already has requested compulsory licenses on two cancer drugs, a move that could become part of a trend. A Pfizer official says such a move "would be a clear disregard of Indian patent laws." (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.